CA2914536A1

CA2914536A1 - Compositions and methods for modulating foxp3 expression

Compositions and methods for modulating foxp3 expression Download PDF

Info

Publication number: CA2914536A1
Authority: CA; Canada
Prior art keywords: foxp3; single stranded; oligonucleotide; stranded oligonucleotide; nucleotides
Prior art date: 2013-06-07
Legal status : Abandoned

Application number

CA2914536A

Other languages

English (en)

French (fr)

Inventor

James Barsoum

Mariano SEVERGNINI

James Mcswiggen

Current Assignee

Translate Bio Inc

Original Assignee

RaNA Therapeutics Inc

Priority date

2013-06-07

Filing date

2014-06-06

Publication date

2014-12-11

2014-06-06 Application filed by RaNA Therapeutics Inc filed Critical RaNA Therapeutics Inc

2014-12-11 Publication of CA2914536A1 publication Critical patent/CA2914536A1/en

Status Abandoned legal-status Critical Current

Links

230000014509 gene expression Effects 0.000 title claims abstract description 112
238000000034 method Methods 0.000 title claims abstract description 94
239000000203 mixture Substances 0.000 title claims abstract description 75
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 586
101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims abstract description 416
102100027581 Forkhead box protein P3 Human genes 0.000 claims abstract description 414
125000003729 nucleotide group Chemical group 0.000 claims description 365
239000002773 nucleotide Substances 0.000 claims description 315
210000001744 T-lymphocyte Anatomy 0.000 claims description 115
241000282414 Homo sapiens Species 0.000 claims description 112
210000004027 cell Anatomy 0.000 claims description 102
108090000623 proteins and genes Proteins 0.000 claims description 81
230000000295 complement effect Effects 0.000 claims description 73
108020004999 messenger RNA Proteins 0.000 claims description 71
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 69
101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 60
102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 60
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 57
102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 56
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 51
239000005547 deoxyribonucleotide Substances 0.000 claims description 47
239000002679 microRNA Substances 0.000 claims description 42
125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 41
230000001965 increasing effect Effects 0.000 claims description 39
201000010099 disease Diseases 0.000 claims description 38
101150027879 FOXP3 gene Proteins 0.000 claims description 37
102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 35
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 35
108020004414 DNA Proteins 0.000 claims description 33
238000012384 transportation and delivery Methods 0.000 claims description 32
102000003814 Interleukin-10 Human genes 0.000 claims description 31
108090000174 Interleukin-10 Proteins 0.000 claims description 31
101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 claims description 30
108700011259 MicroRNAs Proteins 0.000 claims description 26
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 25
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 25
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 21
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 16
239000008194 pharmaceutical composition Substances 0.000 claims description 16
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 14
230000003247 decreasing effect Effects 0.000 claims description 12
230000001594 aberrant effect Effects 0.000 claims description 9
229960002685 biotin Drugs 0.000 claims description 8
235000020958 biotin Nutrition 0.000 claims description 8
239000011616 biotin Substances 0.000 claims description 8
229940104302 cytosine Drugs 0.000 claims description 8
230000005931 immune cell recruitment Effects 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
125000002652 ribonucleotide group Chemical group 0.000 claims description 7
238000011144 upstream manufacturing Methods 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
108091028664 Ribonucleotide Proteins 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
239000002336 ribonucleotide Substances 0.000 claims description 4
239000008366 buffered solution Substances 0.000 claims description 2
101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 claims 4
125000002345 steroid group Chemical group 0.000 claims 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 134
230000003213 activating effect Effects 0.000 abstract description 14
230000002708 enhancing effect Effects 0.000 abstract description 8
102000002272 Polycomb Repressive Complex 2 Human genes 0.000 description 141
108010000597 Polycomb Repressive Complex 2 Proteins 0.000 description 141
150000007523 nucleic acids Chemical class 0.000 description 35
102000039446 nucleic acids Human genes 0.000 description 33
108020004707 nucleic acids Proteins 0.000 description 33
230000004048 modification Effects 0.000 description 32
238000012986 modification Methods 0.000 description 32
238000011282 treatment Methods 0.000 description 32
102000004169 proteins and genes Human genes 0.000 description 24
108020004459 Small interfering RNA Proteins 0.000 description 23
-1 CPP Chemical compound 0.000 description 22
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 22
150000001875 compounds Chemical class 0.000 description 22
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 22
239000000523 sample Substances 0.000 description 22
208000035475 disorder Diseases 0.000 description 21
230000000692 anti-sense effect Effects 0.000 description 20
108091046869 Telomeric non-coding RNA Proteins 0.000 description 19
210000003289 regulatory T cell Anatomy 0.000 description 18
210000001519 tissue Anatomy 0.000 description 18
238000003556 assay Methods 0.000 description 17
PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 17
PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 17
230000003827 upregulation Effects 0.000 description 17
101001010835 Homo sapiens Intraflagellar transport protein 74 homolog Proteins 0.000 description 16
102100029997 Intraflagellar transport protein 74 homolog Human genes 0.000 description 16
241000699670 Mus sp. Species 0.000 description 16
230000000694 effects Effects 0.000 description 15
238000009472 formulation Methods 0.000 description 15
208000023275 Autoimmune disease Diseases 0.000 description 14
239000013642 negative control Substances 0.000 description 14
230000027455 binding Effects 0.000 description 13
239000000090 biomarker Substances 0.000 description 13
208000027866 inflammatory disease Diseases 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 12
239000003814 drug Substances 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
108091070501 miRNA Proteins 0.000 description 12
239000000843 powder Substances 0.000 description 12
235000000346 sugar Nutrition 0.000 description 12
230000001363 autoimmune Effects 0.000 description 11
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
101100128497 Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / IAM 13836 / NRRL 3357 / JCM 12722 / SRRC 167) lnaC gene Proteins 0.000 description 10
101001018097 Homo sapiens L-selectin Proteins 0.000 description 10
102100033467 L-selectin Human genes 0.000 description 10
125000000217 alkyl group Chemical group 0.000 description 10
241000894007 species Species 0.000 description 10
RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 9
108091007767 MALAT1 Proteins 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
239000002243 precursor Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
102100025137 Early activation antigen CD69 Human genes 0.000 description 8
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 8
108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 8
102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 8
230000037396 body weight Effects 0.000 description 8
210000000349 chromosome Anatomy 0.000 description 8
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
230000000699 topical effect Effects 0.000 description 8
102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
229930024421 Adenine Natural products 0.000 description 7
208000022559 Inflammatory bowel disease Diseases 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
108091093037 Peptide nucleic acid Proteins 0.000 description 7
238000011529 RT qPCR Methods 0.000 description 7
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 7
229960000643 adenine Drugs 0.000 description 7
235000012000 cholesterol Nutrition 0.000 description 7
239000012634 fragment Substances 0.000 description 7
239000001257 hydrogen Substances 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
238000001990 intravenous administration Methods 0.000 description 7
230000002685 pulmonary effect Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
229940107161 cholesterol Drugs 0.000 description 6
230000006870 function Effects 0.000 description 6
101150045098 lnaA gene Proteins 0.000 description 6
210000004379 membrane Anatomy 0.000 description 6
239000012528 membrane Substances 0.000 description 6
239000002777 nucleoside Substances 0.000 description 6
150000003833 nucleoside derivatives Chemical class 0.000 description 6
239000002245 particle Substances 0.000 description 6
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
229940035893 uracil Drugs 0.000 description 6
101710163270 Nuclease Proteins 0.000 description 5
201000004681 Psoriasis Diseases 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
238000013461 design Methods 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
238000007914 intraventricular administration Methods 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
230000008569 process Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
239000004055 small Interfering RNA Substances 0.000 description 5
125000006850 spacer group Chemical group 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
201000000596 systemic lupus erythematosus Diseases 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 4
102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 4
208000007465 Giant cell arteritis Diseases 0.000 description 4
108010033040 Histones Proteins 0.000 description 4
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
108091081021 Sense strand Proteins 0.000 description 4
108091027568 Single-stranded nucleotide Proteins 0.000 description 4
108091027967 Small hairpin RNA Proteins 0.000 description 4
230000006044 T cell activation Effects 0.000 description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
150000001408 amides Chemical group 0.000 description 4
238000010171 animal model Methods 0.000 description 4
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000002771 cell marker Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
229940014144 folate Drugs 0.000 description 4
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
235000019152 folic acid Nutrition 0.000 description 4
239000011724 folic acid Substances 0.000 description 4
230000009368 gene silencing by RNA Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
125000001921 locked nucleotide group Chemical group 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000003753 real-time PCR Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000007921 spray Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
230000002194 synthesizing effect Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
230000008685 targeting Effects 0.000 description 4
206010043207 temporal arteritis Diseases 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
RHCSKNNOAZULRK-APZFVMQVSA-N 2,2-dideuterio-2-(3,4,5-trimethoxyphenyl)ethanamine Chemical compound NCC([2H])([2H])C1=CC(OC)=C(OC)C(OC)=C1 RHCSKNNOAZULRK-APZFVMQVSA-N 0.000 description 3
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 3
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 3
108091023037 Aptamer Proteins 0.000 description 3
101150075175 Asgr1 gene Proteins 0.000 description 3
208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
206010009900 Colitis ulcerative Diseases 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
208000009329 Graft vs Host Disease Diseases 0.000 description 3
102100033636 Histone H3.2 Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
101000866766 Homo sapiens Polycomb protein EED Proteins 0.000 description 3
101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
239000004952 Polyamide Substances 0.000 description 3
102100031338 Polycomb protein EED Human genes 0.000 description 3
102100030702 Polycomb protein SUZ12 Human genes 0.000 description 3
201000006704 Ulcerative Colitis Diseases 0.000 description 3
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
125000000753 cycloalkyl group Chemical group 0.000 description 3
201000001981 dermatomyositis Diseases 0.000 description 3
210000004207 dermis Anatomy 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
208000037902 enteropathy Diseases 0.000 description 3
210000002615 epidermis Anatomy 0.000 description 3
208000024908 graft versus host disease Diseases 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000006028 immune-suppresssive effect Effects 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
208000028774 intestinal disease Diseases 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
239000007927 intramuscular injection Substances 0.000 description 3
238000007913 intrathecal administration Methods 0.000 description 3
238000011813 knockout mouse model Methods 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000011987 methylation Effects 0.000 description 3
238000007069 methylation reaction Methods 0.000 description 3
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
208000008795 neuromyelitis optica Diseases 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000003285 pharmacodynamic effect Effects 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229920002647 polyamide Polymers 0.000 description 3
229920000768 polyamine Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
108091007428 primary miRNA Proteins 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000003380 propellant Substances 0.000 description 3
150000003230 pyrimidines Chemical class 0.000 description 3
230000007115 recruitment Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
239000003982 sigma receptor ligand Substances 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
238000012360 testing method Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
239000012096 transfection reagent Substances 0.000 description 3
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
229940045145 uridine Drugs 0.000 description 3
230000002792 vascular Effects 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
235000019155 vitamin A Nutrition 0.000 description 3
239000011719 vitamin A Substances 0.000 description 3
229940045997 vitamin a Drugs 0.000 description 3
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 2
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
108020005345 3' Untranslated Regions Proteins 0.000 description 2
108020003589 5' Untranslated Regions Proteins 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 2
229960005508 8-azaguanine Drugs 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
208000008190 Agammaglobulinemia Diseases 0.000 description 2
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 2
101100048436 Caenorhabditis elegans unc-1 gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
239000004380 Cholic acid Substances 0.000 description 2
108010077544 Chromatin Proteins 0.000 description 2
208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
241001559589 Cullen Species 0.000 description 2
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
208000021866 Dressler syndrome Diseases 0.000 description 2
108700039887 Essential Genes Proteins 0.000 description 2
206010018364 Glomerulonephritis Diseases 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
229930010555 Inosine Natural products 0.000 description 2
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
208000005615 Interstitial Cystitis Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000012309 Linear IgA disease Diseases 0.000 description 2
208000003250 Mixed connective tissue disease Diseases 0.000 description 2
201000002481 Myositis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
206010034277 Pemphigoid Diseases 0.000 description 2
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
208000025237 Polyendocrinopathy Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
102100029812 Protein S100-A12 Human genes 0.000 description 2
101710110949 Protein S100-A12 Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010042276 Subacute endocarditis Diseases 0.000 description 2
206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000000735 allogeneic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000002214 arabinonucleotide Substances 0.000 description 2
208000027625 autoimmune inner ear disease Diseases 0.000 description 2
230000037429 base substitution Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
235000019416 cholic acid Nutrition 0.000 description 2
229960002471 cholic acid Drugs 0.000 description 2
210000003483 chromatin Anatomy 0.000 description 2
201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
230000036541 health Effects 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
102000053917 human FOXP3 Human genes 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000008938 immune dysregulation Effects 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
201000008319 inclusion body myositis Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960003786 inosine Drugs 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
230000009437 off-target effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 2
RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000004713 phosphodiesters Chemical group 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
208000005987 polymyositis Diseases 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000047 product Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
208000002574 reactive arthritis Diseases 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000003161 ribonuclease inhibitor Substances 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000012385 systemic delivery Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
150000003568 thioethers Chemical class 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
INEMUVRCEAELBK-UHFFFAOYSA-N 1,1,1,2-tetrafluoropropane Chemical compound CC(F)C(F)(F)F INEMUVRCEAELBK-UHFFFAOYSA-N 0.000 description 1
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
JDJVDRPZECIOLV-UHFFFAOYSA-N 2-chloro-7h-purin-8-amine Chemical compound ClC1=NC=C2NC(N)=NC2=N1 JDJVDRPZECIOLV-UHFFFAOYSA-N 0.000 description 1
HLLCNVLEVVFTJB-UHFFFAOYSA-N 2-fluoro-2-methylbutane Chemical compound CCC(C)(C)F HLLCNVLEVVFTJB-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
YNFSUOFXEVCDTC-UHFFFAOYSA-N 2-n-methyl-7h-purine-2,6-diamine Chemical compound CNC1=NC(N)=C2NC=NC2=N1 YNFSUOFXEVCDTC-UHFFFAOYSA-N 0.000 description 1
101150098072 20 gene Proteins 0.000 description 1
101150057657 27 gene Proteins 0.000 description 1
OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 1
KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
208000035657 Abasia Diseases 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 description 1
208000026872 Addison Disease Diseases 0.000 description 1
108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
102000008682 Argonaute Proteins Human genes 0.000 description 1
108010088141 Argonaute Proteins Proteins 0.000 description 1
206010003267 Arthritis reactive Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
206010071577 Autoimmune hyperlipidaemia Diseases 0.000 description 1
206010064539 Autoimmune myocarditis Diseases 0.000 description 1
208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 1
206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
208000005024 Castleman disease Diseases 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000024699 Chagas disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008609 Cholangitis sclerosing Diseases 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
108091028075 Circular RNA Proteins 0.000 description 1
102000008169 Co-Repressor Proteins Human genes 0.000 description 1
108010060434 Co-Repressor Proteins Proteins 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
208000010007 Cogan syndrome Diseases 0.000 description 1
208000011038 Cold agglutinin disease Diseases 0.000 description 1
206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
206010011258 Coxsackie myocarditis Diseases 0.000 description 1
208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101100173970 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) fluG gene Proteins 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
206010064212 Eosinophilic oesophagitis Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
208000004332 Evans syndrome Diseases 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
101001092912 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) Small archaeal modifier protein 1 Proteins 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019263 Heart block congenital Diseases 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
206010019939 Herpes gestationis Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000011787 Histone Methyltransferases Human genes 0.000 description 1
108010036115 Histone Methyltransferases Proteins 0.000 description 1
101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
101100120550 Homo sapiens FOXP3 gene Proteins 0.000 description 1
101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000801088 Homo sapiens Transmembrane protein 201 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000031814 IgA Vasculitis Diseases 0.000 description 1
208000010159 IgA glomerulonephritis Diseases 0.000 description 1
206010021263 IgA nephropathy Diseases 0.000 description 1
208000021330 IgG4-related disease Diseases 0.000 description 1
208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000031781 Immunoglobulin G4 related sclerosing disease Diseases 0.000 description 1
208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
108090000908 Interferon regulatory factor 2 Proteins 0.000 description 1
102100029838 Interferon regulatory factor 2 Human genes 0.000 description 1
206010022557 Intermediate uveitis Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
206010024434 Lichen sclerosus Diseases 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000027530 Meniere disease Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
108091060287 Mir-30 microRNA precursor Proteins 0.000 description 1
208000024599 Mooren ulcer Diseases 0.000 description 1
208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
101100264174 Mus musculus Xiap gene Proteins 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
206010071579 Neuronal neuropathy Diseases 0.000 description 1
208000003435 Optic Neuritis Diseases 0.000 description 1
206010053869 POEMS syndrome Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 1
208000004788 Pars Planitis Diseases 0.000 description 1
208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
208000008223 Pemphigoid Gestationis Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
241000009328 Perro Species 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 1
208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
102100032442 Protein S100-A8 Human genes 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108020005093 RNA Precursors Proteins 0.000 description 1
230000026279 RNA modification Effects 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
208000033464 Reiter syndrome Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
101710090029 Replication-associated protein A Proteins 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
108010071000 Retinoblastoma-Binding Protein 7 Proteins 0.000 description 1
102000007503 Retinoblastoma-Binding Protein 7 Human genes 0.000 description 1
206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
206010039705 Scleritis Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
208000002286 Susac Syndrome Diseases 0.000 description 1
206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
208000001106 Takayasu Arteritis Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
206010071574 Testicular autoimmunity Diseases 0.000 description 1
206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 1
102100033708 Transmembrane protein 201 Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
208000026928 Turner syndrome Diseases 0.000 description 1
108700036309 Type I Plasminogen Deficiency Proteins 0.000 description 1
206010064996 Ulcerative keratitis Diseases 0.000 description 1
206010047642 Vitiligo Diseases 0.000 description 1
108091007416 X-inactive specific transcript Proteins 0.000 description 1
108091035715 XIST (gene) Proteins 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002015 acyclic group Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000005600 alkyl phosphonate group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
208000004631 alopecia areata Diseases 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000005122 aminoalkylamino group Chemical group 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000002215 arabinonucleoside Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
208000010216 atopic IgE responsiveness Diseases 0.000 description 1
208000006424 autoimmune oophoritis Diseases 0.000 description 1
201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
206010071578 autoimmune retinopathy Diseases 0.000 description 1
208000010928 autoimmune thyroid disease Diseases 0.000 description 1
208000029407 autoimmune urticaria Diseases 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
208000000594 bullous pemphigoid Diseases 0.000 description 1
239000001273 butane Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
150000001841 cholesterols Chemical class 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
208000013507 chronic prostatitis Diseases 0.000 description 1
208000024376 chronic urticaria Diseases 0.000 description 1
201000010002 cicatricial pemphigoid Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
201000004395 congenital heart block Diseases 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000003210 demyelinating effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229920003045 dextran sodium sulfate Polymers 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
208000019479 dysautonomia Diseases 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
230000005684 electric field Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
201000000708 eosinophilic esophagitis Diseases 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
238000009162 epigenetic therapy Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
208000002980 facial hemiatrophy Diseases 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
230000030279 gene silencing Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
208000018090 giant cell myocarditis Diseases 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
102000053969 human EZH1 Human genes 0.000 description 1
102000056255 human EZH2 Human genes 0.000 description 1
238000011577 humanized mouse model Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000010468 interferon response Effects 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
206010071570 ligneous conjunctivitis Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
206010063344 microscopic polyangiitis Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
GZCNJTFELNTSAB-UHFFFAOYSA-N n'-(7h-purin-6-yl)hexane-1,6-diamine Chemical compound NCCCCCCNC1=NC=NC2=C1NC=N2 GZCNJTFELNTSAB-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
208000025215 nuclear ribonucleic acid Diseases 0.000 description 1
230000001293 nucleolytic effect Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
201000005580 palindromic rheumatism Diseases 0.000 description 1
244000052769 pathogen Species 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000008038 pharmaceutical propellant Substances 0.000 description 1
208000001297 phlebitis Diseases 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
125000004437 phosphorous atom Chemical group 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
208000018290 primary dysautonomia Diseases 0.000 description 1
201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
208000009954 pyoderma gangrenosum Diseases 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
101150054338 ref gene Proteins 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
208000009169 relapsing polychondritis Diseases 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
230000000754 repressing effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
208000010157 sclerosing cholangitis Diseases 0.000 description 1
238000010187 selection method Methods 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
231100000245 skin permeability Toxicity 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
150000003431 steroids Chemical group 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000758 substrate Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
150000003456 sulfonamides Chemical group 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
150000003457 sulfones Chemical group 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
208000009174 transverse myelitis Diseases 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1